

Theradiag: Combined General Meeting of shareholders of June 25, 2020 on second call

Voting results and resolutions

Croissy-Beaubourg, June 25, 2020 6:00 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in *in vitro* diagnostics and theranostics, informs its shareholders that its Combined General Meeting was held on second call in closed session, without shareholders or other people allowed to assist being physically present, on Thursday 25 June 2020 at 2:00 pm at the Company's registered office and chaired by Mr. Pierre Morgon, Chairman of the Board of Directors.

Following this Combined General Meeting held on second call, Theradiag informs its shareholders that the number of shares held by shareholders who voted by mail or by proxy was 2,006,369, representing a quorum of 23.218%.

Theradiag's shareholders voted all the resolutions presented in the way recommended by the Board of Directors.

The Company wishes to sincerely thank all of its shareholders for their commitment to the voting process and for their support.

The detailed voting results by resolution at this Combined General Meeting are the following:

	Resolution n°	Resolutions	N° of votes FOR	N° of votes AGAINST	N° of ABSTENTION	Votes	%	Result of the vote
Ordinary General Meeting	1	Approval of financial statements	1 866 057	138 791	77 783	For	93,08%	Adopted
						Against	6,92%	
						Abstention	3,74%	
	2	Approval of expenses and liabilities (art. 39 CGI)	1 936 613	62 644	83 374	For	96,87%	Adopted
						Against	3,13%	
						Abstention	4,00%	
	3	Allocation of annual income	1 848 265	158 960	75 406	For	92,08%	Adopted
						Against	7,92%	
						Abstention	3,62%	
	4	Approval of regulated agreements	1 920 199	76 400	86 032	For	96,17%	Adopted
						Against	3,83%	
						Abstention	4,13%	
	5	Ratification of the appointment of Mr. Gejia OUYANG as Board member	1 761 451	216 661	104 519	For	89,05%	Adopted
						Against	10,95%	
						Abstention	5,02%	
	6	Renewal of Mr. Gejia OUYANG's mandate as a Board member	1 747 573	292 034	43 024	For	85,68%	Adopted
						Against	14,32%	
						Abstention	2,07%	
	7	Share buyback	1 870 677	185 527	26 427	For	90,98%	Adopted
						Against	9,02%	
						Abstention	1,27%	

	Resolution n°	Resolutions	N° of votes FOR	N° of votes AGAINST	N° of ABSTENTION	Votes	%	Result of the vote
Extraordinary General Meeting	8	Reduction of capital due to losses by way of a reduction in the nominal value of the shares	1 744 469	303 659	34 503	For	85,17%	Adopted
						Against	14,83%	
						Abstention	1,66%	
	9	Capital increase with pre-emptive subscription rights	1 789 251	257 299	36 081	For	87,43%	Adopted
						Against	12,57%	
						Abstention	1,73%	
	10	Capital increase without pre-emptive subscription rights via a public offering	1 451 041	592 962	38 628	For	70,99%	Adopted
						Against	29,01%	
						Abstention	1,86%	
	11	Capital increase without pre-emptive subscription rights via a private placement	1 477 771	576 547	28 313	For	71,93%	Adopted
						Against	28,07%	
						Abstention	1,36%	
	12	Capital increase without pre-emptive subscription rights for certain categories of beneficiaries	1 447 247	602 303	33 081	For	70,61%	Adopted
						Against	29,39%	
						Abstention	1,59%	
	13	Increase in the number of shares by virtue of the 4 previous resolutions	1 732 927	314 650	35 054	For	84,63%	Adopted
						Against	15,37%	
						Abstention	1,68%	
	14	Share purchase warrants allotment	1 598 934	447 104	36 593	For	78,15%	Adopted
						Against	21,85%	
Abstention						1,76%		
15	Free share allotment	1 648 692	413 335	20 604	For	79,95%	Adopted	
					Against	20,05%		
					Abstention	0,98%		
16	Capital increase reserved for employees	644 230	1 416 301	22 100	For	31,26%	Rejected	
					Against	68,74%		
					Abstention	1,06%		
17	Setting of the global threshold	1 813 751	230 159	38 721	For	88,74%	Adopted	
					Against	11,26%		
					Abstention	1,86%		
18	Reduction of the share capital via the cancellation of shares	1 831 028	216 981	34 622	For	89,40%	Adopted	
					Against	10,60%		
					Abstention	1,66%		
19	Modification of the articles of association	1 791 526	240 144	50 961	For	88,18%	Adopted	
					Against	11,82%		
					Abstention	2,45%		
20	Powers to carry out formalities	1 882 838	166 557	33 236	For	91,87%	Adopted	
					Against	8,13%		
					Abstention	1,60%		

The minutes of this Combined General Meeting will be made available soon on the Company's website (in French): <https://www.theradiag.com/en/investors/shareholder-information/general-meeting/>

Financial calendar:

- **H1 2020 revenue**, Tuesday, July 21, 2020
- **H1 2020 results**, Monday, September 21, 2020



About Theradiag

Theradiag is the market leader in biotherapy monitoring. Capitalizing on its expertise in the diagnostics market, the Company has been developing, manufacturing and marketing innovative *in vitro* diagnostic (IVD) tests for over 30 years.

Theradiag pioneered “theranostics” testing (combining therapy with diagnosis), which measures the efficacy of biotherapy in the treatment of chronic inflammatory diseases. Going beyond mere diagnosis, theranostics aims to help clinicians set up “customized treatment” for each patient. This method favors the individualization of treatment, evaluation of its efficacy and the prevention of drug resistance. In response to this challenge, Theradiag develops and markets the CE-marked TRACKER® range, a comprehensive solution of inestimable medical value.

The Company is based in Marne-la-Vallée, near Paris, has operations in over 70 countries and employs over 60 people. In 2019, the Company posted revenue of €9.6 million. The Theradiag share is listed on Euronext Growth Paris (ISIN: FR0004197747) and is eligible for the French PEA-PME personal equity plan. For more information about Theradiag, please visit our website: www.theradiag.com



Theradiag

Bertrand de Castelnaud

CEO/Managing Director

Tel.: +33 (0)1 64 62 10 12

contact@theradiag.com

NewCap

Financial Communications &

Investor Relations

Sandrine Boussard-Gallien

Claire Riffaud

Tel.: +33 (0)1 44 71 94 94

theradiag@newcap.eu

NewCap

Media Relations

Nicolas Mérigeau

Tel.: +33 (0)1 44 71 94 98

nmerigeau@newcap.fr